Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies

Chinezu, Laura; Vasiljevic, Alexandre; Jouanneau, Emmanuel; François, P.; Borda, Angela; Trouillas, Jacqueline; Raverot, Gérald

doi:10.1016/j.humpath.2013.08.007

Cited by 91 publications

(64 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The introduction of highly specific rabbit monoclonal antibodies has allowed the reassessment of the expression of SSTR1, SSTR2a, SSTR3 and SSTR5 in normal and neoplastic tissues (36,37,38,39), including pituitary adenomas (15,17,40,41). We confirmed a positive …”

Section: Discussionsupporting

confidence: 62%

Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study

Iacovazzo

Carlsen²,

Lugli

et al. 2016

European Journal of Endocrinology

139

109

View full text Add to dashboard Cite

Aim: To gather data regarding factors predicting responsiveness to pasireotide in acromegaly. Patients and methods: SSTR2a, SSTR3, SSTR5, AIP, Ki-67 and the adenoma subtype were evaluated in somatotroph adenomas from 39 patients treated post-operatively with somatostatin analogues (SSAs). A standardized SSTR scoring system was applied (scores 0-3). All patients received first-generation SSAs, and 11 resistant patients were subsequently treated with pasireotide LAR. Results: None of the patients with negative or cytoplasmic-only SSTR2a expression (scores 0-1) were responsive to firstgeneration SSAs, as opposed to 20% (score 2) and 50% of patients with a score of 3 (PZ0.04). None of the patients with an SSTR5 score of 0-1 were responsive to pasireotide, as opposed to 5/7 cases with a score of 2 or 3 (PZ0.02). SSTR3 expression did not influence first-generation SSAs or pasireotide responsiveness. Tumours with low AIP were resistant to first-generation SSAs (100 vs 60%; PZ0.02), while they had similar responsiveness to pasireotide compared to tumours with conserved AIP expression (50 vs 40%; PZ0.74). Tumours with low AIP displayed reduced SSTR2 (SSTR2a scores 0-1 44.4 vs 6.7%; PZ0.006) while no difference was seen in SSTR5 (SSTR5 scores 0-1 33.3 vs 23.3%; PZ0.55). Sparsely granulated adenomas responded better to pasireotide compared to densely granulated ones (80 vs 16.7%; PZ0.04). Conclusion: The expression of SSTR5 might predict responsiveness to pasireotide in acromegaly. AIP deficient and sparsely granulated adenomas may benefit from pasireotide treatment. These results need to be confirmed in larger series of pasireotide-treated patients.

show abstract

Section: Discussionsupporting

confidence: 62%

Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study

Iacovazzo

Carlsen²,

Lugli

et al. 2016

European Journal of Endocrinology

139

109

View full text Add to dashboard Cite

show abstract

“…Otherwise, unnecessary repeats and reports of IHC experiments with no clear conclusion will be the consequence, as recently shown by examples in the field of receptors for somatostatin and GLP1 [1,2,12,13]. Implementation of the above-mentioned tests would, therefore, not only considerably add to the quality of published IHC papers, but also help in reproducing important new data and permitting science to progress on a safer track.…”

mentioning

confidence: 99%

Strict rules are needed for validation of G-protein-coupled receptor immunohistochemical studies in human tissues

Reubi

2014

Endocrine

View full text Add to dashboard Cite

“…Putting most of the above-mentioned recommendations into practice will likely prevent unnecessary controversies and reduce experimental discrepancies, as recently shown by examples in the field of receptors for somatostatin, chemokines, and glucagonlike peptide 1 (3,4,10,11,23,24).…”

Section: Optimal Formalin Fixationmentioning

confidence: 99%

In Vitro Evaluation of Molecular Tumor Targets in Nuclear Medicine: Immunohistochemistry Is One Option, but Under Which Conditions?

Reubi

2017

J Nucl Med

View full text Add to dashboard Cite

The identification of new molecular targets for diagnostic and therapeutic applications using in vitro methods is an important challenge in nuclear medicine. One such method is immunohistochemistry, increasingly popular because it is easy to perform. This review presents the case for conducting receptor immunohistochemistry to evaluate potential molecular targets in human tumor tissue sections. The focus is on the immunohistochemistry of G-protein-coupled receptors, one of the largest families of cell surface proteins, representing a major class of drug targets and thus playing an important role in nuclear medicine. This review identifies common pitfalls and challenges and provides guidelines on performing such immunohistochemical studies. An appropriate validation of the target is a prerequisite for developing robust and informative new molecular probes.

show abstract

Expression of somatostatin receptors, SSTR2A and SSTR5, in 108 endocrine pituitary tumors using immunohistochemical detection with new specific monoclonal antibodies

Cited by 91 publications

References 28 publications

Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study

Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study

Strict rules are needed for validation of G-protein-coupled receptor immunohistochemical studies in human tissues

In Vitro Evaluation of Molecular Tumor Targets in Nuclear Medicine: Immunohistochemistry Is One Option, but Under Which Conditions?

Contact Info

Product

Resources

About